WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2024)
Top diagnostic & research stocks in 2024 ranked by overall Zen Score. See the best diagnostic & research stocks to buy now, according to analyst forecasts for the diagnostics & research industry.

Industry: Diagnostics & Research
Ticker
Company
Country
Market Cap
Shares
Institutional %
Insider %
Net Insider (L12M)
Net Insider (L3M)
FONR
FONAR CORP
United States
$143.34M6,710,80747.70%3.51%
STRR
STAR EQUITY HOLDINGS INC
United States
$14.06M15,848,2023.66%96.34%Net BuyingNet Selling
IDXX
IDEXX LABORATORIES INC
United States
$44.86B83,089,38187.71%1.68%Net SellingNet Selling
RVTY
REVVITY INC
United States
$12.97B123,529,82186.51%2.53%Net BuyingNet Buying
CRL
CHARLES RIVER LABORATORIES INTERNATIONAL INC
United States
$13.91B51,349,77096.79%3.21%Net SellingNet Selling
MEDP
MEDPACE HOLDINGS INC
United States
$12.43B30,759,28127.34%72.66%Net SellingNet Selling
ICLR
ICON PLC
Ireland
$27.71B82,495,08695.64%0.00%
QGEN
QIAGEN NV
Netherlands
$9.81B228,202,75561.40%0.00%
ENZ
ENZO BIOCHEM INC
United States
$65.06M51,225,73431.93%48.12%Net Selling
SHC
SOTERA HEALTH CO
United States
$3.40B282,832,20061.96%38.04%Net SellingNet Selling
TMO
THERMO FISHER SCIENTIFIC INC
United States
$221.62B381,312,26889.26%0.87%Net SellingNet Selling
A
AGILENT TECHNOLOGIES INC
United States
$42.64B293,055,28487.43%1.18%Net BuyingNet Selling
LH
LABORATORY CORP OF AMERICA HOLDINGS
United States
$18.37B84,100,00095.77%1.44%Net SellingNet Selling
CSTL
CASTLE BIOSCIENCES INC
United States
$608.02M27,449,98384.08%15.92%Net SellingNet Selling
DHR
DANAHER CORP
United States
$184.72B739,701,72575.94%24.06%Net BuyingNet Selling
TWST
TWIST BIOSCIENCE CORP
United States
$1.98B57,818,02288.34%11.66%Net SellingNet Selling
SERA
SERA PROGNOSTICS INC
United States
$295.07M32,425,66134.04%21.12%Net SellingNet Selling
NEOG
NEOGEN CORP
United States
$3.42B216,520,29698.61%1.39%Net Buying
DGX
QUEST DIAGNOSTICS INC
United States
$14.74B110,707,29388.06%1.77%Net SellingNet Selling
MTD
METTLER TOLEDO INTERNATIONAL INC
United States
$28.59B21,478,70594.58%4.52%Net SellingNet Buying
WAT
WATERS CORP
United States
$20.38B59,202,62692.46%7.54%Net SellingNet Selling
XGN
EXAGEN INC
United States
$27.40M17,235,75136.96%63.04%Net SellingNet Selling
ACRS
ACLARIS THERAPEUTICS INC
United States
$87.95M70,925,04256.85%43.15%Net SellingNet Selling
IQV
IQVIA HOLDINGS INC
United States
$45.90B181,500,00053.95%46.05%Net SellingNet Selling
NTRA
NATERA INC
United States
$11.04B120,757,87778.37%21.63%Net SellingNet Buying
EXAS
EXACT SCIENCES CORP
United States
$12.54B181,530,96788.62%3.40%Net SellingNet Selling
PSNL
PERSONALIS INC
United States
$75.25M50,503,88943.52%18.39%Net SellingNet Buying
DRIO
DARIOHEALTH CORP
Israel
$45.05M29,442,53229.42%53.98%
OLK
OLINK HOLDING AB (PUBL)
Sweden
$2.92B124,342,71530.18%0.00%
FLGT
FULGENT GENETICS INC
United States
$646.33M29,784,77148.02%42.49%Net SellingNet Selling
NEO
NEOGENOMICS INC
United States
$2.01B127,610,03972.39%27.61%Net SellingNet Selling
GH
GUARDANT HEALTH INC
United States
$2.51B121,712,72464.43%35.57%Net SellingNet Buying
STIM
NEURONETICS INC
United States
$141.64M29,756,05350.13%49.87%Net SellingNet Selling
DMTK
DERMTECH INC
United States
$24.31M34,623,44315.75%77.74%Net SellingNet Selling
BGLC
BIONEXUS GENE LAB CORP
Malaysia
$12.47M17,667,6630.59%97.91%
BNR
BURNING ROCK BIOTECH LTD
China
$74.54M102,396,20819.66%0.00%
RDNT
RADNET INC
United States
$3.33B68,475,44364.36%35.64%Net Selling
BIAF
BIOAFFINITY TECHNOLOGIES INC
United States
$19.19M9,502,2431.64%43.03%Net BuyingNet Buying
APDN
APPLIED DNA SCIENCES INC
United States
$6.96M16,978,7039.45%72.88%
PRPO
PRECIPIO INC
United States
$9.51M1,420,1250.61%99.39%
MDXH
MDXHEALTH SA
Belgium
$7.00M27,038,09411.79%88.21%
BDSX
BIODESIX INC
United States
$138.63M96,942,06117.45%72.13%Net BuyingNet Selling
CDNA
CAREDX INC
United States
$548.33M51,778,52379.68%20.32%Net SellingNet Selling
GTH
GENETRON HOLDINGS LTD
China
$123.44M457,743,5300.74%0.00%
LAB
STANDARD BIOTOOLS INC
United States
$786.22M290,117,93016.74%33.18%Net BuyingNet Buying
NDRA
ENDRA LIFE SCIENCES INC
United States
$6.40M11,035,6591.19%8.73%Net Buying
CHEK
CHECK-CAP LTD
Israel
$18.19M5,849,7561.07%0.00%
PRPH
PROPHASE LABS INC
United States
$116.75M18,045,0299.36%57.17%
XWEL
XWELL INC
United States
$7.06M4,179,6311.65%98.35%Net BuyingNet Selling
OPK
OPKO HEALTH INC
United States
$836.39M696,991,66717.43%82.57%Net BuyingNet Buying
NOTV
INOTIV INC
United States
$282.15M25,790,68018.17%43.71%Net Buying
ME
23ANDME HOLDING CO
United States
$256.91M482,916,63627.87%2.59%Net BuyingNet Selling
VNRX
VOLITIONRX LTD
United States
$62.13M82,068,4427.76%40.12%Net BuyingNet Selling
ISPC
ISPECIMEN INC
United States
$2.11M9,087,4674.31%71.05%Net Buying
GENE
GENETIC TECHNOLOGIES LTD
Australia
$667.11k115,417,2460.02%0.00%
MYGN
MYRIAD GENETICS INC
United States
$1.92B89,874,88692.31%7.69%Net SellingNet Selling
PRE
PRENETICS GLOBAL LTD
Hong Kong
$47.56M11,743,43410.43%0.00%
PMD
PSYCHEMEDICS CORP
United States
$16.83M5,742,76122.46%50.15%Net Selling
ILMN
ILLUMINA INC
United States
$21.82B158,900,00089.29%1.97%Net SellingNet Buying
OCX
ONCOCYTE CORP
United States
$24.20M8,260,7623.63%96.37%Net Buying
AWH
ASPIRA WOMEN's HEALTH INC
United States
$32.04M10,336,8340.84%99.16%Net Buying
MMA
ALTA GLOBAL GROUP LTD
Australia
N/A10,223,0790.00%0.00%
TRIB
TRINITY BIOTECH PLC
Ireland
$15.55M152,430,2843.95%0.00%
CNTG
CENTOGENE NV
Germany
$19.59M27,595,8359.75%0.00%
TTOO
T2 BIOSYSTEMS INC
United States
$12.15M4,050,2940.56%99.44%Net Selling
MYNZ
MAINZ BIOMED NV
Germany
$16.10M15,631,5211.48%0.00%

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Mar 2024?

According to Zen Score, the 3 best diagnostic & research stocks to buy right now are:

1. Fonar (NASDAQ:FONR)


Fonar (NASDAQ:FONR) is the top diagnostic & research stock with a Zen Score of 47, which is 20 points higher than the diagnostic & research industry average of 27. It passed 14 out of 33 due diligence checks and has strong fundamentals. Fonar has seen its stock return 38.7% over the past year, overperforming other diagnostic & research stocks by 34 percentage points.

2. Idexx Laboratories (NASDAQ:IDXX)


Idexx Laboratories (NASDAQ:IDXX) is the second best diagnostic & research stock with a Zen Score of 46, which is 19 points higher than the diagnostic & research industry average of 27. It passed 15 out of 33 due diligence checks and has strong fundamentals. Idexx Laboratories has seen its stock return 10.61% over the past year, overperforming other diagnostic & research stocks by 6 percentage points.

Idexx Laboratories has an average 1 year price target of $584.00, an upside of 8.16% from Idexx Laboratories's current stock price of $539.93.

Idexx Laboratories stock has a consensus Buy recommendation according to Wall Street analysts. Of the 5 analysts covering Idexx Laboratories, 60% have issued a Strong Buy rating, 0% have issued a Buy, 40% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Star Equity Holdings (NASDAQ:STRR)


Star Equity Holdings (NASDAQ:STRR) is the third best diagnostic & research stock with a Zen Score of 46, which is 19 points higher than the diagnostic & research industry average of 27. It passed 18 out of 38 due diligence checks and has strong fundamentals. Star Equity Holdings has seen its stock return 3.74% over the past year, underperforming other diagnostic & research stocks by -1 percentage points.

What are the diagnostic & research stocks with highest dividends?

Out of 7 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Qiagen Nv (NYSE:QGEN)


Qiagen Nv (NYSE:QGEN) has an annual dividend yield of 2.98%, which is 1 percentage points higher than the diagnostic & research industry average of 1.61%.

Qiagen Nv's dividend payout ratio of 85.3% indicates that its dividend yield is sustainable for the long-term.

2. Quest Diagnostics (NYSE:DGX)


Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 2.13%, which is 1 percentage points higher than the diagnostic & research industry average of 1.61%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 37.4% indicates that its dividend yield is sustainable for the long-term.

3. Laboratory Of America Holdings (NYSE:LH)


Laboratory Of America Holdings (NYSE:LH) has an annual dividend yield of 1.32%, which is the same as the diagnostic & research industry average of 1.61%. Laboratory Of America Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Laboratory Of America Holdings's dividend has not shown consistent growth over the last 10 years.

Laboratory Of America Holdings's dividend payout ratio of 60% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks up?

Diagnostic & research stocks were up 0.28% in the last day, and down -0.17% over the last week. Opko Health was the among the top gainers in the diagnostics & research industry, gaining 12.15% yesterday.

OPKO Health shares are trading higher after Labcorp announced it will acquire select assets of OPKO's BioReference Health for a purchase price of $237.5 million.

What are the most undervalued diagnostic & research stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued diagnostic & research stocks right now are:

1. Star Equity Holdings (NASDAQ:STRR)


Star Equity Holdings (NASDAQ:STRR) is the most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Star Equity Holdings has a valuation score of 71, which is 49 points higher than the diagnostic & research industry average of 22. It passed 5 out of 7 valuation due diligence checks.

Star Equity Holdings's stock has gained 3.74% in the past year. It has underperformed other stocks in the diagnostic & research industry by -1 percentage points.

2. Enzo Biochem (NYSE:ENZ)


Enzo Biochem (NYSE:ENZ) is the second most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Enzo Biochem has a valuation score of 71, which is 49 points higher than the diagnostic & research industry average of 22. It passed 5 out of 7 valuation due diligence checks.

Enzo Biochem's stock has dropped -47.74% in the past year. It has underperformed other stocks in the diagnostic & research industry by -52 percentage points.

3. Fonar (NASDAQ:FONR)


Fonar (NASDAQ:FONR) is the third most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Fonar has a valuation score of 71, which is 49 points higher than the diagnostic & research industry average of 22. It passed 5 out of 7 valuation due diligence checks.

Fonar's stock has gained 38.7% in the past year. It has overperformed other stocks in the diagnostic & research industry by 34 percentage points.

Are diagnostic & research stocks a good buy now?

45.24% of diagnostic & research stocks rated by analysts are a buy right now. On average, analysts expect diagnostic & research stocks to rise by 0.55% over the next year.

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 37.37x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.